Fri.Mar 29, 2024

article thumbnail

GLP-1 generics would be dramatically cheaper than U.S. price of Ozempic, study shows, but still profitable

STAT

Diabetes drugs are too expensive in the U.S., and insulin is infamously six to 13 times more expensive here than in comparable high-income countries. And blockbuster GLP-1 drugs, too, could be a lot less expensive, according to an investigation published this week in JAMA Network Open, with a simple change: robust generic competition. The study, led by Melissa Barber, a Yale postdoctoral fellow, and conducted in collaboration with Doctors Without Borders, a nonprofit medical organization working

Diabetes 362
article thumbnail

To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach

PharmaVoice

Rivus’ controlled metabolic accelerators are an emerging new potential competitor to popular weight loss and diabetes drugs from Novo Nordisk and Eli Lilly.

Diabetes 162
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Why researchers think human milk could repair the gut microbiome and reduce infections

STAT

For babies who are breastfed, their first source of sustenance is filled with proteins, sugars, hormones, vitamins, and minerals — just the right amount of nutrients for an infant. That milk could also lower the risk of asthma , diabetes, and allergies. And it could make low-birth-weight, preterm babies up to 10 times less likely to develop necrotizing enterocolitis , a common intestinal disorder.

Diabetes 361
article thumbnail

Bristol Myers says KRAS drug succeeds in key trial

BioPharma Dive

Confirmatory results for Krazati, which Bristol Myers acquired via its buyout of Mirati, could help the drug win full approval while Amgen has been set back.

117
117
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

STAT+: Pharmalittle: We’re reading about Wegovy insurance coverage, Zepbound shortages, and more

STAT

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still being formulated, but we do hope to promenade with the official mascots, catch up on our reading, and maybe stare at the telly now and then. Of course, we are also planning another listening party, where the rotation will include this , this , this and this.

301
301
article thumbnail

The Rising Tide of Biopharma Manufacturing Costs

Pharmaceutical Commerce

In this Pharmaceutical Commerce video interview, Barry Heavey, Life Sciences Supply Chain Lead, Accenture, discusses the specific factors contributing to rising manufacturing costs.

104
104

More Trending

article thumbnail

Report claims WuXi shared US client IP with China

pharmaphorum

Report claims US intelligence services advised the authors of the BIOSECURE Act that WuXi AppTec shared confidential data on US clients with the Chinese government

103
103
article thumbnail

STAT+: Up and down the ladder: The latest comings and goings

STAT

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.  That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

258
258
article thumbnail

AstraZeneca Gains FDA Nod for Ultomiris, a Treatment for Managing NMOSD

PharmaTech

FDA has approved AstraZeneca's Ultomiris, marking the first and only long-acting C5 complement inhibitor for patients with NMOSD.

98
article thumbnail

Disappointment for BMS as Zeposia fails Crohn’s study

pharmaphorum

Bristol-Myers Squibb's Zeposia has failed to outperform placebo in its first phase 3 test in Crohn's disease

100
100
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

The Role of GLP-1 Therapies in Type 2 Diabetes Prevention and Treatment

Compounding Pharmacy of America

An exploration of how proper diet, exercise, and a regiment of supplements combined with GLP-1 therapies can prevent and treat type 2 diabetes. The post The Role of GLP-1 Therapies in Type 2 Diabetes Prevention and Treatment appeared first on The Compounding Pharmacy of America.

article thumbnail

FDA approves Gilead’s Vemlidy sNDA for paediatric HBV patients

Pharmaceutical Business Review

This sNDA extends the indication of Vemlidy, a once a day 25mg tablet for usage in children aged six years and above weighing a minimum of 25kg with compensated liver disease. Vemlidy, a targeted prodrug of tenofovir, was initially approved by the US regulator in 2016 for adults with chronic HBV infection and compensated liver disease. The recent approval builds on a 2022 decision which allowed its use in paediatric patients aged 12 years and above.

article thumbnail

GAO Report on Clinical Research Inspections Encourages FDA to Care for its Clinical Inspection Program

FDA Law Blog: Biosimilars

By John W.M. Claud & Kalie E. Richardson — While Covid is in the rear view for most of us, FDA has had a tough time shaking off the effects of the pandemic on its inspection output. Inspections went down—way down—during the pandemic. In March 2020 , FDA temporarily postponed all foreign and domestic and routine surveillance facility inspections.

article thumbnail

New tentative approval for MYLAN drug efavirenz, emtricitabine and tenofovir alafenamide

Drug Patent Watch

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.

59
article thumbnail

Pharma Pulse 3/29/24: Social Media Users Turn to Twitter for Guidance on Birth Control, Wider Availability of Oral Contraceptives & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

105
105
article thumbnail

Arvinas gets grant for treatment of prostate cancer with specific compounds

Pharmaceutical Technology

Discover how Arvinas Inc's newly granted patent for compounds treating prostate cancer could revolutionize healthcare. Learn more about the potential for new drugs and therapies.

article thumbnail

The backbone of breakthroughs: Insights into clinical trial supply management

pharmaphorum

Explore the key aspects of clinical trial supply management, including insights on Clinigen and its role in supporting clinical research trials. Learn how this backbone of breakthroughs can drive success in clinical trials.

52
article thumbnail

Yield10 Bioscience gets grant for genetically engineered oilseed plant expressing plant protein

Pharmaceutical Technology

Discover the groundbreaking patent by Yield10 Bioscience Inc for a genetically engineered oilseed plant expressing a plant protein, revolutionizing biotechnology in agriculture.

52
article thumbnail

Today’s Most Promising Therapeutic Areas for Dealmaking

Pharmaceutical Commerce

In this Pharmaceutical Commerce video interview, Joerg Tritschler, a partner in Simon-Kucher’s life sciences division, discusses the hottest therapeutic settings for dealmaking activity at the moment—and one platform approach in particular poised to be at the center of future M&A and licensing pursuits.

52
article thumbnail

Sun Pharmaceutical Industries gets grant for dermal patch system for collecting physiological samples

Pharmaceutical Technology

Discover the innovative dermal patch system by Sun Pharmaceutical Industries Ltd for efficient and minimally invasive physiological sample collection. Patent US11877848B2 revolutionizes sample processing with a unique design.

52
article thumbnail

Fierce Females in the Life Science Space

PharmExec

In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.

52
article thumbnail

Crinetics Pharmaceuticals gets grant for patent granted for somatostatin modulators for treating hormone-related conditions

Pharmaceutical Technology

Discover how Crinetics Pharmaceuticals Inc's patent for compounds modulating somatostatin activity can suppress hormone secretion in mammals. Explore the detailed framework for hormone modulation and SSTR2 activity regulation.

article thumbnail

A Leading Fast-Food Chain Saves Millions on Direct Material Category With GEP

Pharma and Life Sciences Blog

A Leading Fast-Food Chain Saves Millions on Direct Material Category With GEP annmarie@AZglo… Fri, 03/29/2024 - 13:13 A global fast-food chain sought to align the supplier base for its $545 million pork category with its corporate animal welfare goals and consolidate spend with key suppliers. The company looked to GEP to help drive this strategic realignment.

52
article thumbnail

Gamida Cell gets grant for method of preparing transplantable NK cell fraction for transplantation

Pharmaceutical Technology

Expand transplantable NK cell fractions for cancer treatment with Gamida Cell's patented method. Culturing, supplementing, and storing cells ensure improved outcomes for cancer patients.

52
article thumbnail

New patent for Slayback Pharma drug PREVDUO

Drug Patent Watch

Annual Drug Patent Expirations for PREVDUO Prevduo is a drug marketed by Slayback Pharma Llc and is included in one NDA. It is available from one supplier.

52
article thumbnail

Rohto Pharmaceutical gets grant for ophthalmic composition for treating myopia with crocetin and ginkgo leaf

Pharmaceutical Technology

Discover Rohto Pharmaceutical's patented ophthalmic composition with crocetin and ginkgo leaf extract, proven to prevent and treat myopia in all ages. Explore the groundbreaking method for treating axial myopia and ocular diseases.

52
article thumbnail

New patent for Eli Lilly drug ZEPBOUND

Drug Patent Watch

Annual Drug Patent Expirations for ZEPBOUND Zepbound is a drug marketed by Eli Lilly And Co and is included in one NDA. It is available from one supplier.

52
article thumbnail

Angelini gets grant for method for labelling reels using robot and application roller

Pharmaceutical Technology

Revolutionize your labeling process with Angelini Spa's patented method using a robot and label printer to efficiently attach printed labels to reels. Patent Publication Number: US11884443B2.

article thumbnail

Automation of Clinical Data Key in Meeting Cell and Gene Therapy Demand

PharmaTech

Can Cellares deliver on the goal to meet total patient demand for cell therapies globally? CEO Fabian Gerlinghaus discusses.

59
article thumbnail

Chong Kun Dang Pharmaceutical gets grant for injectable composition of testosterone undecanoate for testosterone deficiency treatment

Pharmaceutical Technology

Discover the innovative injectable composition of testosterone undecanoate by Chong Kun Dang Pharmaceutical Corporation. Patented for treating testosterone deficiency, this composition offers enhanced stability and ease of use during injection.

52
article thumbnail

New patent expiration for Vifor Pharma drug VELTASSA

Drug Patent Watch

Annual Drug Patent Expirations for VELTASSA Veltassa is a drug marketed by Vifor Pharma and is included in one NDA. It is available from one supplier.

52
article thumbnail

CSL gets grant for method of reducing GVHD risk in hct patients with a1at

Pharmaceutical Technology

Discover how CSL Ltd's patented method using alpha-1 antitrypsin (A1AT) can reduce the risk of graft versus host disease in hematopoietic cell transplantation patients. Published as US11857610B2, this groundbreaking approach offers hope for improved outcomes.

52
article thumbnail

New patent for Genentech Inc drug XOFLUZA

Drug Patent Watch

Annual Drug Patent Expirations for XOFLUZA Xofluza is a drug marketed by Genentech Inc and is included in two NDAs. It is available from one supplier.

52
article thumbnail

A Further Examination of Pharmacy Benefit Managers

Pharmaceutical Commerce

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.

article thumbnail

New patent for Biogen Idec drug SPINRAZA

Drug Patent Watch

Annual Drug Patent Expirations for SPINRAZA Spinraza is a drug marketed by Biogen Idec and is included in one NDA. It is available from one supplier.

52